Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
- Status
- TERMINATED
- Phase
- PHASE2
Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC
- Status
- UNKNOWN
- Phase
- PHASE2
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
SCION: SABR and Checkpoint Inhibition of NSCLC
- Status
- WITHDRAWN
- Phase
- PHASE2
Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
- Status
- RECRUITING
- Phase
- PHASE2
SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Lung Cancer With Copanlisib and Durvalumab
- Status
- COMPLETED
- Phase
- PHASE1
Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy
- Status
- RECRUITING
- Phase
- PHASE2
Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases
- Status
- WITHDRAWN
- Phase
- PHASE2